Personalised cancer prevention

• Recommended from the age of 30; the genetic test only needs to be taken once in a lifetime.
• The test is performed using a simple cheek swab.
• You will receive your results within 6 weeks. Doctors can also access the results through the Estonian Health Portal (Terviseportaal).
• Any further breast examinations may be provided free of charge through referrals under the national breast cancer screening programme.
• We offer the option of a post-test consultation.

Why is personalised cancer prevention important?

• Breast cancer often has a genetic component. Every woman’s risk of developing the disease is different. Women with a high genetic risk may develop breast cancer as early as their 30s or 40s, and the disease may be more aggressive at a younger age. This must be carefully considered when planning screening and follow-up examinations.
• Breast cancer and related deaths can often be prevented through timely measures, even before symptoms appear. When detected early, breast cancer is treatable.
• New technologies make it possible to identify genetic risk even in women who have no family history of breast cancer or no previously identified genetic mutations.
• With this service, you will receive a personalised medical prevention plan that takes into account your genetic profile, age, sex and ethnic background.

Who can benefit from this service?

• Women under 50: Particularly beneficial for identifying individual risk and starting regular screening years before the national screening programme begins.
• Women with no family history of breast cancer: The service is also suitable for women whose close relatives have never had cancer. Genetic risk may still be elevated, and innovative polygenic risk score (PRS) technology can now help identify it.
• Women with a family history of breast cancer: If breast cancer has occurred repeatedly among close relatives, we can also provide a free referral to a medical geneticist, if necessary, to investigate hereditary genetic risks in greater detail. The need for a referral is assessed based on a relevant questionnaire.

• If you have already consulted a geneticist but no known mutations have been identified, Antegenesis’ innovative technology can provide additional insight into your genetic risk.
• Women aged 50 and over: The service is also suitable for women already participating in the national screening programme. You can find out whether you may need more frequent monitoring than the screening programme’s standard interval of once every two years.

What does the service include?

• The service is based on genetic risk testing using innovative polygenic risk score (PRS) technology in healthcare.
• Antegenesis’ advanced, evidence-based PRS technology calculates the combined effect of 2,803 genetic variants associated with breast cancer to determine your genetic risk level.
• By combining your PRS result with your personal background (ethnicity, age and sex), we provide accurate risk assessments and personalised medical recommendations for further screening and healthy lifestyle choices, helping to prevent breast cancer and detect it at an early stage.
• The test is simple and convenient. All you need to do is collect a sample from the inside of your cheek using a cotton swab.

What will the test results tell you?

Your results will include:

• Your polygenic breast cancer risk score.
• An interpretation of your test results, together with clinical recommendations for prevention and screening and clear next steps.
• An estimate of your likelihood of developing breast cancer over the next 10 years, compared with a woman at average risk.
• A comprehensive set of clinical guidelines for healthcare professionals to support evidence-based, personalised breast cancer prevention and appropriate medical follow-up.
• An optional post-test consultation, during which you can discuss your genetic risk in combination with lifestyle-related risk factors.

Book an appointment for the test with a midwife at a breast clinic, a gynaecologist or a breast specialist (mammologist).

• Recommended for men aged 40 and over. The genetic test only needs to be taken once in a lifetime.
• The test is performed using a simple cheek swab.
• You will receive your results within 6 weeks. Doctors can also access the results through the Estonian Health Portal (Terviseportaal).
• Any further examinations for prostate cancer are arranged through appointments with an andrologist or urologist.
• We offer the option of a post-test consultation.

Why should you start by assessing your genetic risk?

• Prostate cancer has a strong genetic component.
• Every man’s risk of developing the disease is different. Men with a high genetic risk may develop prostate cancer as early as their 30s or 40s, and the disease may be more aggressive even at a younger age. This must be carefully considered when planning screening and follow-up examinations.
• In many cases, cancer and related premature deaths can be prevented through timely measures, even before symptoms appear. When detected early, prostate cancer is generally treatable.
• Personalised cancer prevention is based on genetic risk assessment. It is a modern, evidence-based healthcare service supported by the latest international scientific research.
• New technologies make it possible to identify genetic risk even in men who have no family history of prostate cancer or no previously identified genetic mutations.
• A PSA test alone may not be sufficient to detect prostate cancer at an early stage, particularly in men with a high genetic risk. It is now possible to identify men who may need additional examinations even when their PSA levels are within the normal range. This is particularly important because a high genetic risk is also associated with a threefold increase in the risk of premature death, often due to late detection of the disease.
• With this service, you will receive a personalised medical prevention plan that takes into account your genetic profile, age, sex and ethnic background.

Who can benefit from this service?

• Personalised prostate cancer prevention is suitable for all men aged 40–70.

• Health-conscious men aged 40 and over: Those who want to take proactive steps to protect their health through modern, evidence-based personalised cancer prevention.
• Men under 50: Particularly beneficial for identifying risks early and starting appropriate screening and follow-up examinations in a timely manner.
• Men with no family history of cancer: The service is also suitable for men whose close relatives have never had cancer. Genetic risk may still be elevated, and our innovative technology can help identify it.
• Men with a family history of prostate cancer: If prostate cancer has occurred repeatedly among close relatives, we can also provide a free referral to a medical geneticist, if necessary, to investigate hereditary genetic risks in greater detail.
• Men who have already consulted a geneticist: If you have previously undergone genetic testing but no known mutations were identified, our innovative technology can provide additional insight into your genetic risk.
• Men aged 60 and over: The service is also suitable for men who already visit a urologist or andrologist for periodic check-ups. You can find out whether you may need more frequent or more comprehensive monitoring.

What does the testing include?

• The service is based on genetic risk testing using innovative polygenic risk score (PRS) technology in healthcare.
• Antegenes’ advanced, evidence-based PRS technology calculates the combined effect of 121 genetic variants associated with prostate cancer to determine your genetic risk level.
• By combining your PRS result with your personal background (ethnicity, age and sex), we provide accurate risk assessments and personalised medical recommendations for further examinations and healthy lifestyle choices, helping to prevent prostate cancer and detect it at an early stage.
• The test is simple and convenient. All you need to do is collect a sample from the inside of your cheek using a cotton swab.

Test results

You will receive your results within 6 weeks. They will be made available in the MyAntegenes patient portal and the national Estonian Health Portal (Terviseportaal). Antegenes will notify you by email when your results are ready.

• The results are based on an analysis of the combined effect of 121 genetic variants associated with prostate cancer.

Your results will include:

• Your polygenic prostate cancer risk score.
• An interpretation of your test results, together with clinical recommendations for prevention and further examinations and clear next steps.
• An estimate of your likelihood of developing prostate cancer over the next 10 years, compared with a man at average risk.
• A comprehensive set of clinical guidelines for healthcare professionals to support evidence-based, personalised prostate cancer prevention and appropriate medical follow-up.

What happens next?

Based on the results of your genetic prostate cancer risk test, men identified as having a high genetic risk will receive a referral for a private MRI scan (as this examination is not yet covered by the Estonian Health Insurance Fund). This will be followed by a consultation with a urologist.

Book an appointment for the test with a urologist.

Why is personalised cancer prevention important?

Breast cancer is often associated with genetic factors. Every woman has an individual risk of developing the disease. In women with a high genetic risk, breast cancer may develop as early as their 30s or 40s and may be more aggressive at a younger age. This should be carefully takeninto account when planning screening and preventive examinations.

Breast cancer and deaths related to the disease can often be preventedthrough timely preventive measures, even before symptoms appear. Cancer detected at an early stage is treatable.

New technologies make it possible to identify genetic risk even in women who have no history of breast cancer in their immediate family and no previously known genetic variants.

The service provides you with a personalised medical prevention plan that takes into account your genetic profile, age, sex, and ethnic background.

Who is this service suitable for?

• Especially beneficial for women under 50, as it can help identify individual risk and, when appropriate, begin regular screening several years before the national screening programme starts.
• Suitable for women with no previous history of cancer in their immediate family. Genetic risk may still be elevated, and the innovativetechnology of polygenic risk score (PRS) assessment can help identify it.
• If breast cancer has occurred repeatedly in your immediate family.Where appropriate, we can also provide a referral to a medical geneticist free of charge to further assess hereditary genetic risks. The need for a referral is evaluated based on a relevant questionnaire.
• If you have already consulted a geneticist but no known mutations were identified. Thanks to Antegenes’ innovative technology, you can gain additional insight into your genetic risk.
• Also suitable for women aged 50 and over who already participate in the national breast cancer screening programme. You can find out whether you may benefit from more frequent monitoring than thenational programme, which currently provides screening every two years.

What does the service include?

The service is based on genetic risk assessment using modern polygenic risk score (PRS) technology.

Antegenes’ advanced, evidence-based PRS technology assesses the combined effect of 2,803 genetic variants associated with breastcancer to determine an individual’s genetic risk level.

By combining the PRS result with your individual background — including ethnic background, age, and sex — we provide personalised risk estimates and medical recommendations for further screening, monitoring, and healthy lifestyle choices, helping to prevent disease and detect it at an early stage.

The test is simple and convenient. A sample is collected from theinside of the cheek using a cotton swab.

What does the test result show?

The results include:

• your polygenic breast cancer risk score;
• an interpretation of the test results together with clinicalrecommendations for prevention and screening, including clear next steps;
• an estimate of your likelihood of developing breast cancer within the next 10 years compared with a woman with average risk;
• detailed clinical guidance for healthcare professionals included in thetest report to support medical decision-making in modern, evidence-based personalised breast cancer prevention.

A post-test consultation is optional. During the consultation, you can further discuss your genetic risks in combination with risk factorsrelated to your lifestyle.

To take the test, book an appointment with a midwife, gynaecologist,or mammologist at the breast clinic.